Skip to main content
. Author manuscript; available in PMC: 2019 Aug 11.
Published in final edited form as: Nat Med. 2019 Feb 11;25(3):477–486. doi: 10.1038/s41591-018-0337-7

Fig. 2. Kaplan-Meier plot of progression-free survival.

Fig. 2

Median progression-free survival (PFS) for patients who received pembrolizumab only in the adjuvant setting was 72.5 days; patients who received neoadjuvant and adjuvant pembrolizumab had a median PFS of 99.5 days (HR = 0.43, 95% CI 0.20 to 0.90; two-sided P = 0.03 by log-rank test).